MiMedx Group, Inc — Earnings Quality Grade B
MDXG · Healthcare
Generally healthy
Screening Summary
Management Signals
Source: SEC EDGAR 8-K Item 5.02, with exhibit links when available
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 66 days, change +8 days YoY
AR growth 35.6% exceeds revenue growth 20.0%
Revenue 20.0%, CFFO 11.8%. Cash follows revenue
Expense Quality
Inventory 6.4% vs COGS 21.5%. Normal
CapEx growth -38.6% vs revenue 20.0%. Normal
SG&A/Gross Profit = 77.0%, exceeds 70%
Gross margin 82.6%, change -0.2pp. Stable
Cash Flow Quality
CFFO/NI = 1.52. Profits backed by cash
FCF $0.1B, FCF/NI = 1.50
Accruals ratio = -7.4%. Low accruals
Cash $0.2B covers debt $0.0B
Balance Sheet Health
Goodwill+Intangibles $0.0B = 13% of equity. Manageable
Debt/EBITDA = 0.2x. Healthy
Other assets 8.4% vs revenue 20.0%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions positive
Goodwill+Intangibles change 8% YoY. Normal
Manipulation Score
M-Score = -2.68 (< -2.22). Unlikely manipulator
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25